Sumain Faisal

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

FDA approves Amphastar’s iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch. Latest Ratings for AMPH Date Firm Action From To Mar 2022 Piper Sandler Maintains Overweight Jan 2022 Piper Sandler Upgrades Neutral Overweight Mar 2021 Wells Fargo Maintains Equal-Weight View More Analyst Ratings for AMPH View the…

Read More